Companies › Nurix Therapeutics
3 active drug programs in 6 registered trials: 4 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NX-5948 Non-covalent BTK inhibitor | BTK | Phase 3 | B-cell Lymphoma; Chronic Lymphocytic Leukemia (CLL) | Jan 2027 |
| NX-2127 Btk inhibitor | – | Phase 1 | Chronic Lymphocytic Leukemia (CLL) | May 2027 |
| NX-1607 Cbl-b inhibitor | CBL-B | Phase 1 | Ovarian Cancer, Epithelial | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05131022 | NX-5948 | Phase 1 | Chronic Lymphocytic Leukemia (CLL) | Oncology | Jan 2027 |
| NCT04830137 | NX-2127 | Phase 1 | Chronic Lymphocytic Leukemia (CLL) | Oncology | May 2027 |
| NCT07221500 | NX-5948 | Phase 2 | Chronic Lymphocytic Leukemia (CLL) | Oncology | Jan 2028 |
| NCT05107674 | NX-1607 | Phase 1 | Ovarian Cancer, Epithelial | Oncology | Feb 2028 |
| NCT07516093 | NX-5948 | Phase 3 | B-cell Lymphoma | Oncology | Oct 2029 |
| NCT07520006 | NX-5948 | Phase 1 | B-cell Lymphoma | Oncology | May 2033 |
Cash and short-term investments of $1.1bn on 2026-08-31; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Compass Therapeutics TransThera Sciences (Nanjing) NOBO Medicine Day One Biopharmaceuticals Nuvalent
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.